Effects of a mushroom mycelium extract on the treatment of XXXX .

@entity1 @entity18277 @entity263 @entity1486
OBJECTIVES: To determine whether supplemental amounts of a polysaccharide/oligosaccharide complex obtained from a @entity18277 ( @entity18277 ) would lower the @entity1486 (PSA) level in @entity1 with @entity263 . METHODS: A total of 62 @entity1 (mean age 73.2 years, range 53.6 to 85.5) with histologically proven @entity263 who had two consecutive elevated PSA readings were accrued to the study during a 3-month period. This was an open-label study in which the @entity1 received oral administration of capsules containing @entity18277 given three times daily for 6 months. The endpoint for the trial was the lowering of the PSA levels. RESULTS: Of the 62 @entity1 enrolled in the study, 61 were assessable. At 4 months, 1 @entity1 withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50% in the PSA level. By 6 months, a total of 23 @entity1 had progression and none had responded. Thirty-eight @entity1 had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these @entity1 could have been included as responders. When the @entity1 ' rates of PSA rise before study entry were analyzed, 4 (7%) had stabilized disease while taking @entity18277 . Thus, the final results for our study @entity1 were 0 with a complete response, 0 with a partial response, 4 (7%) with stable disease, and 23 of 61 with progression while taking @entity18277 . CONCLUSIONS: @entity18277 alone is ineffective in the treatment of @entity263 .
